Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 13, 2026 11:08 ET | Source: Zelluna ASA

Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial

First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation TrustZI-MA4-1 is the world’s first MAGE-A4-targeting TCR-NK therapy in clinical developmentZIMA-101...
July 13, 2026 11:08 ET | Source: Zelluna ASA

Zelluna doserer første pasient med ZI-MA4-1 i fase 1-studien ZIMA-101

Første pasient dosert med ZI-MA4-1 ved The Christie NHS Foundation Trust. ZI-MA4-1 er verdens første MAGE-A4-rettede TCR-NK-terapi som nå testes i pasienter for første gangMed ZIMA-101 testes...
July 02, 2026 08:34 ET | Source: Zelluna ASA

Zelluna ASA - Grant of Share Options

Oslo, 2 July 2026: On the basis of the authorization granted by the General Meeting on 23 April 2026 for the Board of Directors of Zelluna ASA (the “Company”, OSE ticker “ZLNA”) to issue shares to...
June 30, 2026 04:13 ET | Source: Zelluna ASA

Zelluna ASA awarded NOK 16 million Research Council of Norway grant

Oslo, 29 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today...
June 30, 2026 04:13 ET | Source: Zelluna ASA

Zelluna ASA tildelt NOK 16 millioner i tilskudd fra Forskningsrådet

Oslo, 29. juni 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogene «off-the-shelf» T-cellereseptor-baserte naturlige dreperceller (TCR-NK) for behandling av solide kreftformer, kunngjør i dag...
June 29, 2026 07:03 ET | Source: Zelluna ASA

Zelluna ASA: Mandatory notification of trade – Return of lent shares following Private Placement

Oslo, 29 June 2026: Reference is made to the stock exchange announcement by Zelluna ASA (the "Company") on 18 June 2026 regarding completion of a private placement of 3,143,958 new shares at a...
June 29, 2026 03:59 ET | Source: Zelluna ASA

Zelluna ASA: New share capital registered

Oslo, Norway, 29 June 2026: Reference is made to the stock exchange announcement published by Zelluna ASA (the “Company”) on 18 June 2026 regarding a successfully placed private placement (the...
June 29, 2026 02:30 ET | Source: Zelluna ASA

Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities

The Royal Marsden NHS Foundation Trust activated as the second clinical site in the ZIMA-101 Phase 1 trialPatient identification, pre-screening and screening activities ongoing at first activated...
June 29, 2026 02:30 ET | Source: Zelluna ASA

Zelluna ASA aktiverer The Royal Marsden som det andre kliniske senteret for ZIMA-101, og utvider kapasiteten for klinisk gjennomføring

The Royal Marsden NHS Foundation Trust aktivert som det andre kliniske senteret i fase 1-studien ZIMA-101Identifisering, pre-screening og screening av pasienter er i gang ved første aktiverte kliniske...
June 26, 2026 10:40 ET | Source: Zelluna ASA

Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided

Oslo, 26 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today...